Abstract
Cytokine-producing CD4+ T cells play a crucial role in the control of Mycobacterium tuberculosis infection; however, there is a delayed appearance of effector T cells in the lungs following aerosol infection. The immunomodulatory cytokine IL-10 antagonizes control of M. tuberculosis infection through mechanisms associated with reduced CD4+ T cell responses. Here, we show that IL-10 overexpression only before the onset of the T cell response impaired control of M. tuberculosis growth; during chronic infection, IL-10 overexpression reduced the CD4+ T cell response without affecting the outcome of infection. IL-10 overexpression early during infection did not, we found, significantly impair the kinetics of CD4+ T cell priming and effector differentiation. However, CD4+ T cells primed and differentiated in an IL-10–enriched environment displayed reduced expression of CXCR3 and, because they did not migrate into the lung parenchyma, their ability to control infection was limited. Importantly, these CD4+ T cells maintained their vasculature phenotype and were unable to control infection, even after adoptive transfer into low IL-10 settings. Together our data support a model wherein, during M. tuberculosis infection, IL-10 acts intrinsically on T cells, impairing their parenchymal migratory capacity and ability to engage with infected phagocytic cells, thereby impeding control of infection.
Highlights
Tuberculosis (TB) remains the worldwide leading cause of death from a single infectious agent.While active intervention is lowering the global incidence of this disease, new tools are required to reach the ambitious goal of the WHO of ending the TB epidemics by 2035
But not late IL-10 production impairs the control of airborne Mycobacterium tuberculosis (Mtb) infection
IL-10 has been associated with increased susceptibility to Mtb infection in humans [27, 28, 30, 31, 36] and in mice [24, 25, 39], the immunological mechanisms underlying this effect are not completely understood
Summary
While active intervention is lowering the global incidence of this disease, new tools are required to reach the ambitious goal of the WHO of ending the TB epidemics by 2035. These tools include improved diagnostic of clinical and subclinical disease and more effective drugs and vaccines [1]. The current TB vaccine Mycobacterium bovis Bacille Calmette-Guérin (BCG) while effective in preventing disseminated forms of pediatric TB [2], is not efficient against adult pulmonary disease [3, 4]. A novel vaccine regimen to protect against pulmonary TB is amongst the highest global health priorities
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have